biolitec AG
biolitec AG: biolitec AG achieved consolidated revenue of Euro 7.5 million in the first
biolitec AG / Key word(s): Quarter Results/Quarter Results 10.02.2011 18:28 Dissemination of an Ad hoc announcement according to § 15 WpHG, transmitted by DGAP - a company of EquityStory AG. The issuer is solely responsible for the content of this announcement. --------------------------------------------------------------------------- biolitec AG achieved consolidated revenue of Euro 7.5 million in the first quarter of the fiscal year 2010/2011 - EBIT improved considerably over the previous year Jena, February 10th, 2011 - biolitec AG, Jena, listed in the Prime Standard of the Frankfurt stock exchange (ISIN DE0005213409), achieved a consolidated revenue of Euro 7.54 million for the first quarter of the fiscal year 2010/2011. Thereby, the revenue was significantly Euro 1.33 million above the previous first quarter. The revenue growth of 21% is attributable to economic recovery of the core markets and the growing demand for biolitec's mainstays of sales, the LIFE(TM) laser treatment of benign prostate hyperplasia (BPH) and the endoluminal laser treatment of veins (ELVeS(TM)). The gross profit amounted to Euro 5.2 million (previous year: Euro 4.5 million) and EBIT amounted to Euro 0.73 million (previous year: Euro 0.63 million). R&D expenditures for the first three months of the fiscal year 2010/2011 of Euro 0.61 million (about 8% of sales) compared to the previous year (Euro 0.65 million) remain on the required level to ensure the companies' long term growth and profitability. Sales costs also remained constant to Euro 2.3 million compared to Euro 2.1 million in the last year's period. biolitec AG's major revenues were generated in Europe and North America. With Euro 3.36 million, sales in North America were clearly up on the previous year's level. European sales amounted to Euro 3.01 million (previous year: Euro 2.5 million), in Asia and ROW biolitec was able to increase revenues by 19% to Euro 1.08 million. The sales in business segment Meditec amounted to Euro 7.13 million in the first quarter of the fiscal year 2010/2011; in the Pharma segment the sales increase to Euro 0.41 million and were rather marginal. The business segment Pharma is primarily defined by biolitec's cancer drug Foscan(R) for patients with head and neck cancer. In some European countries the costs of Foscan(R) treatment are covered by governmental organisations. Foscan(R) is a PDT drug especially for patients for whom no other treatment can be found. The photodynamic therapy (PDT) is a medical treatment for special tumors. It is a combination of laser light of a specific wavelength, oxygen and a light-sensitive substance which destroys cancer cells. In the segment proctology biolitec has launched one of the most innovative laser therapies. A procedure for the photocoagulation of haemorrhoidal arteries with HeLP(TM) (Haemorrhoid Laser Procedure), a minimally invasive and secure intervention is patent pending. Furthermore, with the LHP technology second to forth degree hemorrhoids can be treated painlessly. With the help of the radial emitting fiber the hemorrhoids can be irradiated from the inside and be shrunk. With FiLaC (Fistula-tract Laser Closure) a minimally invasive treatment option for fistulas is now available. Because that is an essential innovation for the treatment of a widespread disease, biolitec sees in it a considerable sales potential for the next fiscal years. For the current business year biolitec expects further increase in sales and profit. 10.02.2011 DGAP's Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. Media archive at www.dgap-medientreff.de and www.dgap.de --------------------------------------------------------------------------- Language: English Company: biolitec AG Otto-Schott-Str.15 07745 Jena Deutschland Phone: +49 (0) 3641 519 53 0 Fax: +49 (0) 3641 519 53 33 E-mail: info@biolitec.de Internet: www.biolitec.de ISIN: DE0005213409 WKN: 521340 Listed: Regulierter Markt in Frankfurt (Prime Standard); Freiverkehr in Berlin, Düsseldorf, Hamburg, München, Stuttgart End of Announcement DGAP News-Service ---------------------------------------------------------------------------
Latest News
Latest Reports
Upcoming Events
No Events found
Webcasts
No Webcasts found